Nektar Therapeutics has successfully priced an upsized public offering, raising approximately $400 million to advance its clinical-stage immunotherapy pipeline. This significant capital infusion is earmarked for critical research and development, including late-stage trials for its lead candidate, rezpegaldesleukin.
